ERLANGEN, May 7, 2024/PRNewswire/ -- Siemens Healthcare today released its results report for the second quarter of the 2024 fiscal year ending March 31, 2024.
Second quarter of fiscal year 2024
- The equipment order shipment ratio reached 1.08
- Compared with the excellent performance in the same period last year, comparable revenue increased by 3%; excluding the rapid COVID-19 antigen testing business, comparable revenue increased by 11.7%
- Compared with the strong performance in the same period last year, the comparable revenue of the imaging diagnosis business increased by 2.6%, and the adjusted profit margin before interest and tax was 20.2%
- Comparable revenue from the laboratory diagnosis business increased by 3.7%; excluding the rapid COVID-19 antigen testing business, comparable revenue increased by 4.1%; the adjusted profit margin before interest and tax was 4.1%, significantly higher than the same period last year
- Compared with strong performance in the same period last year (comparable increase of 27%), Varian's comparable revenue decreased slightly by 2.1%; the adjusted profit margin before interest and tax increased significantly to 16.4%
- Compared with the strong performance in the same period last year, the comparable revenue of the clinical treatment business increased by 8.0%; the adjusted profit margin before interest and tax was 16.2%
- The overall adjusted profit margin before interest and tax reached 15.1%
- Adjusted basic earnings per share of €0.55
2024 outlook
We confirm that Siemens Healthcare's comparable revenue for the 2024 fiscal year is expected to increase by 4.5% to 6.5%. Excluding the revenue from the rapid COVID-19 antigen testing business, the comparable revenue growth rate is expected to be 5.0% to 7.0%. Adjusted basic earnings per share are expected to be between €2.10 and €2.30.
Meng Tianqi, CEO of Siemens Healthcare ((Bernd Montag): “Even compared with the excellent performance of the same period last year, Siemens Healthcare has successfully continued its growth trajectory this year. After an overall strong performance in the first half of FY2024, we are once again making steady progress towards our fiscal year goals.”